๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Treatment and planning decisions in non-small cell carcinoma of the lung: An Australasian patterns of practice study

โœ Scribed by C.S. Hamilton; J.W. Denham; D.J. Joseph; D.S. Lamb; N.A. Spry; A.J. Gray; C.H. Atkinson; C.J. Wynne; A. Abdelaal; P.V. Bydder; P.J. Chapman; J.H.L. Matthews; G. Stevens; D. Ball; J. Kearsley; J.B. Ashcroft; P. Janke; A. Gutmann

Book ID
108473175
Publisher
Elsevier Science
Year
1992
Tongue
English
Weight
744 KB
Volume
4
Category
Article
ISSN
1433-2981

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Treatment of small cell lung carcinoma i
Treatment of small cell lung carcinoma in the elderly
โœ Esther Dajczman; Li Yi Fu; David Small; Norman Wolkove; Harvey Kreisman ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 625 KB

## BACKGROUND. The number of elderly people with small cell lung carcinoma (SCLC) is increasing and currently nearly 25% are older than 70 years. Elderly patients may not tolerate intensive therapy and, therefore, often do not receive such treatment. Additionally, age may be an independent predicto

Cisplatin, etoposide, and mitomycin in t
Cisplatin, etoposide, and mitomycin in the treatment of non-small cell carcinoma of the lung. A pilot study
โœ Stephen Davis; Maurizio Tomato; Lucio Crino; Mari Antonetta Colozza; Kenneth Lub ๐Ÿ“‚ Article ๐Ÿ“… 1986 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 192 KB ๐Ÿ‘ 2 views

A total of 39 patients with non-small cell carcinoma of the lung (NSCL) were treated with cisplatin, etoposide, and mitomycin. A major response rate (complete response + partial response) was seen in 15 patients (39%). Median survival for all patients was 340 days; median survival of the responding